The industry association biosaxony e. V. will launch a digital campaign on 22 June 2021 to honour the commitment of Saxon biotech and medtech companies.
Companies and institutions in the Saxon biotech and medtech industry have developed and launched products and services to combat the corona pandemic in a very short time with know-how and high entrepreneurial commitment. Their innovations are used worldwide for the diagnosis of the virus as well as for the production and transport of vaccines or can be used for the ventilation of intensive care patients.
With Saxon innovations against the pandemic
“We want to help the biotech and medtech solutions from Saxony to become more prominent and show what a powerful contribution our members make in times of crisis to helping people worldwide,” says Dr. Oliver Uecke, CEO of biosaxony e. V. and COO of Lipotype GmbH.
The Saxon industry association has therefore initiated a digital campaign, which is intended to raise awareness among the actors in business and science as well as the general public of the innovations from Saxony to combat the corona pandemic. At the same time, the campaign aims to promote the perception of Saxony as one of the most dynamic life sciences locations in Europe.
“The bundling of the specific competencies of the numerous high-performance companies in an innovation cluster shows how successful an overarching cooperation can be in times of crisis. It not only promotes faster response times to close supply bottlenecks, but also enables access to the international market for smart medical devices and innovative therapies,” says André Hofmann, Managing Director of biosaxony e. V.
Campaign highlights the performance of the Saxon biotech site
Under the motto “SOLVE-CoV-2”, which takes up the well-known spelling of “SARS-CoV-2”, the campaign presents ten of these high-performance solutions from Saxony’s biotechnology and medical technology clusters as examples. They will be bundled on the website www.biosaxony.de/solvecov2 and presented successively in the digital professional network LinkedIn in the period from 22 June to 14 July 2021.
GENEWIZ Germany is the prelude to the series with its portfolio of DNA analyses, gene syntheses and related services, which has contributed to the development of effective methods for the prevention, investigation and therapy of the novel coronavirus. It ends with the presentation of biosaxony’s commitment. On the initiative of biosaxony, a network of 3D printing experts was launched in a very short time. This ensured that clinics and other health care providers could be supplied with missing materials such as face shield sights, manufactured in the 3D printing and injection molding process.
Unbridled growth despite corona pandemic
The importance of the Saxon biotechnology and medical technology industry has increased significantly in recent years and continues to develop with great dynamism. In Leipzig and Dresden, there are now about 50 successful biotech companies. Some of them have emerged from the renowned universities and research institutes of the Free State. In the meantime, companies from other regions or from abroad are increasingly also settled in order to benefit from the excellent research network in Saxony. A total of 230 small and medium-sized medical technology companies research and produce in the Free State of Saxony. In 2022, a special highlight for the Saxon life sciences industry is on the agenda: Europe’s largest biotech trade fair BioEurope will take place in Leipzig in 2022 and bring together the continent’s top researchers and decision-makers.
Appeal: Softening of the eligibility criteria for subordinated loans
The corona pandemic also did not lead to the collapse of Saxony as a life sciences location. On the contrary, the industry continues to grow steadily. In the Corona year, biosaxony e. V. was unable to record any loss of sales or insolvencies at its member companies. In order for this trend to continue after the pandemic, research-based SMEs must be given more support. Currently, these are rather put obstacles in the way by the legislator. The reason: Loans that are indispensable for companies in the R&D sector have no longer been considered as equity replacement by federal and state funding institutions since the end of 2020. The background to this is the very rigorous interpretation of a corresponding EU regulation in Germany. “This is a disaster for research-based companies, as they usually have a low equity ratio and are dependent on funding. The questionable interpretation of the EU regulation creates massive competitive disadvantages for German companies from research and development, as other EU countries interpret the regulation much more softly. This is practically a complete exclusion from state funding instruments, including the research allowance. We fear that this will result in innovation holes of unimagined proportions,” says André Hofmann. So now it is time for politics. The appeal of industry associations such as biosaxony e.V. is clear: only with a readjustment of the criteria for loans in research can it be prevented that innovations and developments at a low level migrate cheaply abroad.
10 Saxon biotech solutions at a glance:
- GENEWIZ offers DNA analysis and gene synthesis to better understand SARS-CoV-2.
- With AProof®, Adversis Pharma has developed test methods for antibody detection.
- Biotype has produced a real-time PCR test in a very short time.
- c-LEcta has developed DENARASE®, an important enzyme for vaccine production.
- Drees & Sommer designs buildings and infrastructure in a resilient and thus pandemic-proof manner.
- Mannin is researching a drug to combat acute lung failure.
- With Next3D, emergency ventilators come from the 3D printer.
- ROBOSCREEN provides reagents required for PCR testing.
- Schaumaplast ensures reliable transport of vaccines with its THERMOCON boxes.
- Biosaxony and network partners produce plastic visors in the 3D printing and injection molding process.
Source: Press release biosaxony of 22.06.2021